Author

P. Valent

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. A. Mangaonkar· 1 shared A. Buradkar· 1 shared A. Czibere· 1 shared A. Di Ruscio· 1 shared A. I. Varela· 1 shared A. Ianevski· 1 shared A. K. Ebralidze· 1 shared A. Maurer· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 8 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Mangaonkar

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

D. Pölöske, H. Sorger, A. Schönbichler, E. D. de Araujo, H. A. Neubauer, A. Orlova, S. H. Timonen, D. I. Abdallah, A. Ianevski, H. Kuusanmäki, M. Surbek, C. Wagner, T. Suske, M. L. Metzelder, M. Bergmann, , R. Moriggl

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

bioRxiv · Oct 12, 2023 · PreprintCancer Biology

Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter

E. van der Kouwe, G. Heller, A. Czibere, L. H. Castilla, R. Delwel, A. Di Ruscio, A. K. Ebralidze, M. Forte, L. Kazianka, C. Kornauth, T. Le, K. Lind, I. A. Monteiro Barbosa, A. Pichler, J. A. Pulikkan, , P. B. Staber

The paper shows that CBF fusions in AML activate the PU.1 antisense promoter, reducing sense PU.1 transcription and blocking myeloid differentiation, similar to T-cell differentiation.

Blood · Oct 14, 2021Peer-reviewedCancer Biology

Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis

M. A. Szymanski de Toledo, M. Gatz, S. Sontag, K. V. Gleixer, G. Eisenwort, K. Feldberg, F. Kluge, R. Guareschi, G. Rossetti, A. S. Sechi, O. Dufva, S. M. Mustjoki, A. Maurer, H. M. Schueler, R. Goetzke, , M. Zenke

This study identifies nintedanib as a novel KIT D816V inhibitor effective against patient-derived neoplastic mast cells in systemic mastocytosis.

bioRxiv · May 6, 2020Cancer Biology

miRNome profiling of clonal stem cells in Ph+ CML

M. S. Ruiz, M. B. Sanchez, S. Bonecker, C. Furtado, D. Koile, P. Yankilevich, S. Cranco, M. d. R. Custidiano, J. Freitas, B. Moiraghi, M. A. Perez, C. Pavlovsky, A. I. Varela, V. Ventriglia, J. C. Sanchez Avalos, , M. Bianchini

This study profiles the miRNome of CML leukemic stem cells and compares it to normal stem cells and healthy donors, identifying global miRNA decreases and metabolic pathway associations.

bioRxiv · Mar 16, 2020Cancer Biology

RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik

This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.

bioRxiv · Dec 23, 2019 · PreprintCancer Biology